NHS patients denied new lung cancer drug after another NICE deadlockCertain untreated lung cancer patients on England’s NHS will have to make do with older drugs after NICE Share XNHS patients denied new lung cancer drug after another NICE deadlockhttps://pharmaphorum.com/news/nice-deadlock/
Call for mandatory disclosure of industry funding of patient groupsExperts have warned that few patient groups have formal policies governing corporate funding and financial transparency, despite widespread Share XCall for mandatory disclosure of industry funding of patient groupshttps://pharmaphorum.com/news/call-for-mandatory-disclosure-of-industry-funding-of-patient-groups/
AstraZeneca commits to being carbon negative by 2030AstraZeneca has announced its ambition to have zero carbon emissions from its global operations by 2025 and to Share XAstraZeneca commits to being carbon negative by 2030https://pharmaphorum.com/news/astrazeneca-commits-to-being-carbon-negative-by-2030/
UK biotech PhoreMost to work with Otsuka on gene therapy projectsBuilding on an R&D tie-up with an Indian stem cell institution last year, UK biotech PhoreMost has begun Share XUK biotech PhoreMost to work with Otsuka on gene therapy projectshttps://pharmaphorum.com/news/uk-biotech-phoremost-to-work-with-otsuka-on-gene-therapy-projects/
Janssen’s Darzalex approved in EU for newly-diagnosed multiple myelomaJanssen’s Darzalex (daratumumab) has been approved in Europe as a combination therapy in newly-diagnosed patients with multiple myeloma. Share XJanssen’s Darzalex approved in EU for newly-diagnosed multiple myelomahttps://pharmaphorum.com/news/janssens-darzalex-approved-in-eu-for-multiple-myeloma/
AI-powered study backs anticoagulants for heart failure patients without AFA new study has found that blood thinning drugs improve outcomes for all heart failure patients, regardless of Share XAI-powered study backs anticoagulants for heart failure patients without AFhttps://pharmaphorum.com/news/ai-powered-study-backs-anticoagulants-for-heart-failure-patients-without-af/
Novartis’ Mayzent EU approval offers SPMS patients new optionNovartis’ Mayzent has been approved in Europe for adults with secondary progressive multiple sclerosis (SPMS) and active disease. Share XNovartis’ Mayzent EU approval offers SPMS patients new optionhttps://pharmaphorum.com/news/novartis-mayzent-eu-approval-offers-spms-patients-new-option/
Durect’s post-op painkiller splits FDA advisory panelAs the US opioid addiction crisis continues, it seems the FDA is less than convinced about the new Share XDurect’s post-op painkiller splits FDA advisory panelhttps://pharmaphorum.com/news/durects-post-op-painkiller-splits-fda-advisory-panel/
WHO criticises lack of big pharma antibiotic R&DBig pharma still continues to look upon antibiotic resistance as somebody else’s problem, the World Health Organization has Share XWHO criticises lack of big pharma antibiotic R&Dhttps://pharmaphorum.com/news/who-bemoans-lack-of-big-pharma-antibiotic-rd/
